Teclistamab dosing in responders: Modeling and simulation results from the MajesTEC-1 study in relapsed/refractory multiple myeloma

This journal article reports on teclistamab dosing for relapsed/refractory multiple myeloma based on MajesTEC-1 modeling. It supports switching responders to 1.5 mg/kg every other week, demonstrating maintained efficacy. Modeling also suggests 3 mg/kg every four weeks may offer comparable response maintenance, which is being evaluated in ongoing phase III studies.